Despite long-term treatment, persistent disease activity and inflammation in D2T RA may stem from a complex interplay of high baseline autoimmunity (RF/ACPA), multi-pathway immune activation (TNF-α/IL-6/JAK-STAT), comorbidities, and socioeconomic barriers limiting optimal therapy access (50–54). Here, IL6 is linked to rheumatoid arthritis.